Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

Jan. 3, 2025 — Much of our knowledge of the protein PD-1, a leading cancer treatment target, comes from studies in mice. In a comprehensive assessment of PD-1, ... Enzyme Promoting Tumor Growth ...

Jan. 6, 2025 — Researchers have developed a way of detecting circulating tumor cells in the bloodstream of pancreatic cancer and lung cancer ... Scientists Develop Scans That Light-Up Aggressive ...

More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.

In this Review, the functional and molecular consequences of pathological hypoxia on male germ cells and fertility are explored, including potential influences on embryo development and ...

Branched organoids embedded in collagen gels can recapitulate the phenotypic landscape and pronounced molecular and morphological heterogeneity of pancreatic ductal adenocarcinoma.

With today’s Aries moon activating your sense of authority, you could be tempted to pull rank and call the shots. Yes, you’ve done more than your share of hard work, but what makes you think ...

As expected, Neo-AgNPs were proven to have great tumor penetration and local release. In situ, the modification was able to direct engineered Tcr-T1 against other HLA-A*2402-positive malignant cancer ...

Trying to force progress? The more you push, the more pushback you’ll receive as the moon clashes with Mars! Frustration over a botched timeline inspires you to take matters into your own hands.

Daily science news on research developments and the latest scientific innovations Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech ...

As a postdoc, he focused on the molecular characterization of cancer and hematopoietic stem cells with Andreas Trumpp at the DKFZ and Jeroen Krijgsveld at EMBL. Daniel joined The EMBO Journal in 2015.